Ardelyx Stock Surges 6%, Adding $44 Million, After Quarterly Loss Nearly Disappears
The drugmaker kept its 2026 targets as IBSRELA sales rose 23% and its net loss narrowed to $737,000.
Ardelyx shares climbed 5.61% to $3.20 in Wednesday trading as of 10:11 a.m. ET, adding $44 million in market value, a day after the drugmaker reported a quarterly net loss of only $737,000.
IBSRELA Carries The Quarter
Ardelyx, which sells the tenapanor-based medicines IBSRELA and XPHOZAH, released results after Tuesday's close: revenue of $127.7 million, up 15.7% from a year earlier.
IBSRELA, approved for adults with irritable bowel syndrome with constipation, rose 23% to $96.3 million. XPHOZAH, which lowers serum phosphorus in dialysis patients, rose only 7% to $29.2 million.
A late-stage tenapanor trial in chronic idiopathic constipation pushed R&D costs to $25.2 million from $18.1 million.
Outlook Held, 2027 Profit Targeted
Management kept all of its 2026 targets, including operating expenses under $500 million. It is targeting profitability in 2027.
The move was on pace to be the stock's biggest one-day gain since May 4, when it rose 6.1%.
A Stock Still Down 48%
Even with Wednesday's gain, Ardelyx shares were down about 48% for the year as of Tuesday's close, while the S&P 500 was up about 11% over the same span. The stock sits far below its highest close of the past year, set on January 21.
Ardelyx's market value stood at $826 million in Wednesday morning trading.
Sources
- Ardelyx: Q3 Earnings Snapshot — Associated Press
- Ardelyx reaffirms 2026 IBSRELA $350M-$370M guidance while targeting profitability in 2027 (NASDAQ:ARDX) | Seeking Alpha — seekingalpha.com
- Ardelyx: Q3 Earnings Snapshot – WTOP News — wtop.com
- BTIG Remains a Buy on Ardelyx (ARDX) - The Globe and Mail — theglobeandmail.com
- Ardelyx (ARDX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates — Yahoo Finance
- The company's filing (Ardelyx) — SEC filing
- Ardelyx — Form 10-Q for the quarter ended 2026-09-30 (quarterly results) — SEC EDGAR